Daily Stock Analysis, SYBX, Synlogic Inc, priceseries

Synlogic Inc. Daily Stock Analysis
Stock Information
Open
2.07
Close
2.10
High
2.13
Low
1.99
Previous Close
2.10
Daily Price Gain
0.00
YTD High
2.48
YTD High Date
Jan 4, 2022
YTD Low
1.39
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.32
YTD Gain
-13.22%
52 Week High
5.10
52 Week High Date
Mar 25, 2021
52 Week Low
1.39
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-1.05
52 Week Gain
-33.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 12. 2016
10.95
Feb 22. 2017
15.71
47 Trading Days
43.48%
Link
LONG
Jun 26. 2017
10.71
Jul 18. 2017
11.80
15 Trading Days
10.16%
Link
LONG
Sep 7. 2017
13.20
Sep 29. 2017
19.06
16 Trading Days
44.39%
Link
LONG
Feb 14. 2018
10.18
Feb 27. 2018
10.80
8 Trading Days
6.12%
Link
LONG
Apr 6. 2018
9.70
May 7. 2018
12.61
21 Trading Days
29.97%
Link
LONG
Aug 24. 2018
9.05
Oct 4. 2018
13.74
28 Trading Days
51.83%
Link
LONG
Feb 7. 2019
8.27
Feb 25. 2019
9.28
11 Trading Days
12.21%
Link
LONG
Jun 14. 2019
7.72
Jul 3. 2019
9.01
13 Trading Days
16.70%
Link
LONG
Dec 5. 2019
2.29
Dec 13. 2019
2.42
6 Trading Days
5.68%
Link
LONG
Jan 14. 2020
2.73
Jan 22. 2020
2.91
5 Trading Days
6.71%
Link
LONG
Jul 15. 2020
2.02
Aug 4. 2020
2.24
14 Trading Days
10.79%
Link
LONG
Jan 13. 2021
3.18
Jan 28. 2021
3.60
10 Trading Days
13.11%
Link
LONG
Feb 2. 2021
3.75
Feb 18. 2021
4.55
11 Trading Days
21.27%
Link
LONG
Jun 10. 2021
3.67
Jun 28. 2021
4.18
12 Trading Days
13.80%
Link
LONG
Jan 28. 2022
1.86
Feb 2. 2022
1.96
3 Trading Days
5.38%
Link
Company Information
Stock Symbol
SYBX
Exchange
NasdaqGM
Company URL
http://www.mirnatherapeutics.com
Company Phone
617-401-9975
CEO
Paul Lammers
Headquarters
Massachusetts
Business Address
301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001527599
About

Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX.

Description

Developing microRNA replacement therapies for liver cancer.